NIAID-sponsored trial of a universal influenza vaccine begins

(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial of an investigational universal influenza vaccine intended to protect against multiple strains of the virus has begun. The study is sponsored by the National Institute of Allergy and Infectious Diseases and is being conducted at US sites that are part of the NIAID-funded Vaccine and Treatment Evaluation Units. The trial is testing an experimental vaccine called M-001 for safety and its ability to produce potenti...